Please assess the completion status of the following clinical trial:

Trial Title: Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will meet DSM-IV criteria for schizophrenia or schizoaffective disorder.~* Current treatment with one or more second generation antipsychotics, except ziprasidone~* On same second generation antipsychotic(s)for at least 56 days~* On same dose of second generation antipsychotic(s)for at least 30 days~* 22-item SANS: Total score (i.e.all items minus global items and poverty of content of speech)greater than 20 or global Rating of Affective Flattening greater than or equal to 3 or global Rating of alogia greater than or equal to 3~* BPRS: Sum of the four positive symptom items less than or equal to 16 (items 4,11,12,15)~* BPRS: Sum of the four Anxiety/Depression Factor items less than or equal to 14 (items 1,2,5,9)~* Simpson-Angus Scale: Total score less than or equal to 8~Exclusion Criteria:~* DSM-IV Major Depressive Disorder within last 6 months~* Current treatment with ziprasidone~* DSM-IV diagnosis of alcohol or substance dependence within the last 6 months~* DSM-IV criteria for alcohol or substance abuse within the last month~* evidence of illicit substance use, as identified with urine toxicology screen~* History of an organic brain disorder, mental retardation,epilepsy, or a medical condition, whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol. See those listed below~* Uncontrolled hypertension defined as BP exceeding 145/90 on 3 consecutive readings despite adequate treatment, pheochromocytoma, melanoma, hepatic insufficiency~* Pregnancy or lactation in females~* Pheochromocytoma~* Melanoma~* Hepatic insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Rasagiline (Type: ACTIVE_COMPARATOR): Treatment with Rasagiline
- Inactive pill (Type: PLACEBO_COMPARATOR): Treatment with Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).